

FOR IMMEDIATE RELEASE

Contact:

Michael Scolaro, Founder and CEO

Augustus BioTarget, Inc.

Phone: 843-281-0380

mscolaro@AugustusBioTarget.com

Web: www.AugustusBioTarget.com

Cancer Research Online Crowdsourcing Campaign Passes 78% of Funding Goal

*Uses an Ancient Indian Spice to Awaken the Immune system
in the Fight Against Cancer*

August 29, 2107 -- An early-stage drug development company in South Carolina has launched an online fundraising campaign to study the ancient spice curcumin in combination with an FDA-approved Immune Checkpoint Inhibitor to fight colon cancer.

Within five days of launch, the company has met 78% of its funding goal on Experiment.com, an online science crowdfunding platform dedicated to scientific research. <https://experiment.com/curcumincancerproject>

A group of scientists working in the US at Augustus BioTarget, Inc., and in Germany at Rodos Biotarget, GmbH, developed a unique nanocarrier drug delivery system, the CLR-TargoSphere®, into which curcumin was encapsulated. This will be studied in mice with colon cancer at the Charles River Labs in North Carolina.

“Our aim is to resurrect the immune response against cancer with targeted curcumin,” said Michael Scolaro, founder of Augustus BioTarget and Chief Investigator. “Curcumin is known to possess significant anti-inflammatory and anti-neoplastic properties. But because it is very poorly absorbed and distributed in the body, it has been impractical for clinical use. Delivering curcumin directly to immune cells that are immobilized by cancers promises to help restore anti-cancer activity.

“Using curcumin in medicine may not secure huge capital investments the way a new iPad does,” he added. “But with the latest advancements in immune system targeting, its use to fight cancer is now within reach.”

###